{"entity":{"id":"nct06587061","kind":"trial","name":"HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial in pancreatic cancer, run by Ruijin Hospital, now recruiting.","summary":"HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer is a phase 2, interventional study registered as NCT06587061 by Ruijin Hospital, with a registry enrolment figure of 30 participants, started 2024-12-03 and due to reach its primary completion in 2027-06. Interventions recorded: HRS-4642+AG. Conditions listed: Pancreatic Cancer. Primary outcome: Adverse events (AEs); Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: \"Pathologically or cytologically confirmed ductal adenocarcinoma of the pancreas; and subjects must have at least one measurable lesion as defined by RECIST v1\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06587061","url":"https://clinicaltrials.gov/study/NCT06587061"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06587061","phase":"2","setting":"An Exploratory Clinical Study of HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","sponsor":"Ruijin Hospital","participation":[{"nct":"NCT06587061","source":"https://clinicaltrials.gov/study/NCT06587061","fetchedAt":"2026-10-07T16:54:49.791Z","studySha256":"b9edb9ec68e5ae833c1bb7fc20724305ffa4fe2fb6b833a0ffb8bf11aa934a6c","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-27","leadSponsor":"Ruijin Hospital","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"80 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":30,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2024-12-03","startedType":"actual","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06587061/","neighbours":{"cancer":[{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}